<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: investment", fill: "#fffdd0"},
{source: "1: investment", target: "1: common shares involves", fill: "#fffdd0"},
{source: "1: investment", target: "2: should carefully", fill: "#eb4c42"},
{source: "2: should carefully", target: "2: specific factors described", fill: "#eb4c42"},
{source: "2: specific factors described", target: "2: cautionary", fill: "#eb4c42"},
{source: "2: cautionary", target: "2: common shares", fill: "#eb4c42"},
{source: "2: should carefully", target: "4: Additional ", fill: "#dea5a4"},
{source: "4: Additional ", target: "4: immaterial could also impair", fill: "#dea5a4"},
{source: "4: immaterial could also impair", target: "4: financial condition", fill: "#dea5a4"},
{source: "4: financial condition", target: "4: operations", fill: "#dea5a4"},
{source: "4: Additional ", target: "5: risks actually", fill: "#96c8a2"},
{source: "5: risks actually", target: "5: financial condition", fill: "#96c8a2"},
{source: "5: financial condition", target: "5: operations could", fill: "#96c8a2"},
{source: "5: operations could", target: "5: adversely affected", fill: "#96c8a2"},
{source: "5: risks actually", target: "7: future growth depends on increased market acceptance", fill: "#a9a9a9"},
{source: "7: future growth depends on increased market acceptance", target: "7: acceptance", fill: "#a9a9a9"},
{source: "7: acceptance", target: "7: INVOS System ", fill: "#a9a9a9"},
{source: "7: future growth depends on increased market acceptance", target: "27: dependent on", fill: "#a9a9a9"},
{source: "27: dependent on", target: "27: distributors", fill: "#a9a9a9"},
{source: "27: distributors", target: "27: independent sales representative firms", fill: "#a9a9a9"},
{source: "27: independent sales representative firms", target: "27: United States", fill: "#a9a9a9"},
{source: "27: dependent on", target: "START_HERE", fill: "#a9a9a9"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Class_B_share">Class B share</a></td>
      <td>In finance, a Class B share or Class C share is a designation for a share class of a common or preferred stock that typically has strengthened voting rights or other benefits compared to a Class A share that may have been created. The equity structure, or how many types of shares are offered, is determined by the corporate charter.B share can also refer to various terms relating to stock classes:\n\nB share (mainland China), a class of stock on the Shanghai and Shenzhen stock exchanges\nB share (NYSE), a class of stock on the New York Stock ExchangeMost of the time, Class B shares may have lower repayment priorities in the event a company declares bankruptcy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Penny_stock">Penny stock</a></td>
      <td>Penny stocks are common shares of small public companies that trade for less than one dollar per share.The U.S. Securities and Exchange Commission (SEC) uses the term "Penny stock" to refer to a security, a financial instrument which represents a given financial value, issued by small public companies that trade at less than $5 per share. Penny stocks are priced over-the-counter, rather than on the trading floor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_equity">Common equity</a></td>
      <td>Common equity is the amount that all common shareholders have invested in a company. Most importantly, this includes the value of the common shares themselves.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Secondary_shares">Secondary shares</a></td>
      <td>In an IPO, secondary shares (in contrast to primary shares) refer to existing shares of common stock that are sold to investors in an offering (see Secondary Market Offering).\nThe selling of these secondary shares may be from existing shareholders.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Assets_under_management">Assets under management</a></td>
      <td>In finance, assets under management (AUM), sometimes called funds under management, measures the total market value of all the financial assets which an individual or financial institution—such as a mutual fund, venture capital firm, or depository institution—or a decentralized network protocol controls, typically on behalf of a client.  These funds may be managed for clients/users or for themselves in the case of a financial institution which has mutual funds or holds its own venture capital.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Life_Insurance_Corporation">Life Insurance Corporation</a></td>
      <td>Life Insurance Corporation of India (LIC) is an Indian statutory insurance and investment corporation headquartered in the city of Mumbai, India. It is under the ownership of Government of India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ivor_Montagu">Ivor Montagu</a></td>
      <td>Ivor Goldsmid Samuel Montagu (23 April 1904, in Kensington, London – 5 November 1984, in Watford) was an English filmmaker, screenwriter, producer, film critic, writer, table tennis player, and Communist activist in the 1930s. He helped to develop a lively intellectual film culture in Britain during the interwar years, and was also the founder of the International Table Tennis Federation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Defence_mechanism">Defence mechanism</a></td>
      <td>In psychoanalytic theory, a defence mechanism (American English: defense mechanism), is an unconscious psychological operation that functions to protect a person from anxiety-producing thoughts and feelings related to internal conflicts and outer stressors.Defence mechanisms may result in healthy or unhealthy consequences depending on the circumstances and frequency with which the mechanism is used. Defence mechanisms (German: Abwehrmechanismen) are psychological strategies brought into play by the unconscious mind to manipulate, deny, or distort reality in order to defend against feelings of anxiety and unacceptable impulses and to maintain one's self-schema or other schemas.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Day_the_Music_Died">The Day the Music Died</a></td>
      <td>On February 3, 1959, American rock and roll musicians Buddy Holly, Ritchie Valens, and "The Big Bopper" J. P. Richardson were killed in a plane crash near Clear Lake, Iowa, together with pilot Roger Peterson. The event later became known as "The Day the Music Died" after singer-songwriter Don McLean referred to it as such in his 1971 song "American Pie".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/North_American_Free_Trade_Agreement">North American Free Trade Agreement</a></td>
      <td>The North American Free Trade Agreement (NAFTA ; Spanish: Tratado de Libre Comercio de América del Norte, TLCAN; French: Accord de libre-échange nord-américain, ALÉNA) was an agreement signed by Canada, Mexico, and the United States that created a trilateral trade bloc in North America. The agreement came into force on January 1, 1994, and superseded the 1988 Canada–United States Free Trade Agreement between the United States and Canada.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Altium">Altium</a></td>
      <td>Altium Limited (formerly known as Protel Systems until 2001) is a publicly traded software company that provides PC-based electronics design software for engineers who design printed circuit boards. Founded as Protel Systems Pty Ltd in Australia in 1985, the company has regional  headquarters in the United States, Australia, China, Europe, and Japan.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hyundai_Veloster">Hyundai Veloster</a></td>
      <td>The Hyundai Veloster (Korean: 현대 벨로스터, romanized: Hyeondae Belloseuteo) is a hatchback coupé first produced in 2011 by Hyundai, with sales beginning in South Korea on March 10, 2011, and in Canada and the United States since the fall of 2011. In South Korea, it is marketed under Hyundai's 'Premium Youth Lab'.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pakistan_Software_Export_Board">Pakistan Software Export Board</a></td>
      <td>Pakistan Software Export Board (PSEB) (Urdu: قومی ہیئت برائے صادراتِ سوفٹ ویئر، پاکستان) is an apex Government body mandated to promote Pakistan's IT Industry in local and international markets. PSEB facilitates the IT industry through a series of projects and programs.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Worley_(company)">Worley (company)</a></td>
      <td>WorleyParsons Limited, branded as Worley after completing the acquisition of Jacobs' Energy, Chemicals &amp; Resources (ECR) division, is an American    Australian engineering company which provides project delivery and consulting services to the resources and energy sectors, and complex process industries.\n\n\n== History ==\n1970s: John Grill (chief executive officer 1975–2012), joined Smith, de Kantzow &amp; Wholohan, which led to the 1976 establishment Wholohan Grill and Partners, a small Australian engineering consultancy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fisher_&amp;_Paykel_Healthcare">Fisher &amp; Paykel Healthcare</a></td>
      <td>Fisher &amp; Paykel Healthcare Corporation Limited (FPH) is a manufacturer, designer and marketer of products and systems for use in respiratory care, acute care, and the treatment of obstructive sleep apnea. Based in New Zealand, their products and systems are sold in around 120 countries worldwide.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/TPG_(ISP)">TPG (ISP)</a></td>
      <td>TPG is an Australian internet service provider that specialises in consumer and business internet services as well as mobile telephone services. As of August 2015, TPG is the second largest internet service provider in Australia and is the largest mobile virtual network operator.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Australian_Vintage">Australian Vintage</a></td>
      <td>Australian Vintage Limited (AVG) is an Australian public company that operates within the wine production industry. It was established by Brian McGuigan with the help of his wife, Fay, and younger brother, Neil McGuigan.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Navy">United States Navy</a></td>
      <td>The United States Navy (USN) is the maritime service branch of the United States Armed Forces and one of the eight uniformed services of the United States. It is the largest and most powerful navy in the world, with the estimated tonnage of its active battle fleet alone exceeding the next 13 navies combined, including 11 U.S. allies or partner nations as of 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/History_of_the_United_States">History of the United States</a></td>
      <td>The history of the lands that became the United States began with the arrival of the first people in the Americas around 15,000 BC. Numerous indigenous cultures formed, and many saw transformations in the 16th century away from more densely populated lifestyles and towards reorganized polities elsewhere.  The European colonization of the Americas began in the late 15th century, however most colonies in what would later become the United States were settled after 1600.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Republican_Party_(United_States)">Republican Party (United States)</a></td>
      <td>The Republican Party, also referred to as the GOP ("Grand Old Party"), is one of the two major contemporary political parties in the United States, along with its main historic rival, the Democratic Party.\nThe GOP was founded in 1854 by anti-slavery activists who opposed the Kansas–Nebraska Act, which allowed for the potential expansion of chattel slavery into the western territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_dollar">United States dollar</a></td>
      <td>The United States dollar (symbol: $; code: USD; also abbreviated US$ or U.S. Dollar, to distinguish it from other dollar-denominated currencies; referred to as the dollar, U.S. dollar, American dollar, or colloquially buck) is the official currency of the United States and several other countries. The Coinage Act of 1792 introduced the U.S. dollar at par with the Spanish silver dollar, divided it into 100 cents, and authorized the minting of coins denominated in dollars and cents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Democratic_Party_(United_States)">Democratic Party (United States)</a></td>
      <td>The Democratic Party is one of the two major contemporary political parties in the United States. It was founded in 1828 by supporters of Andrew Jackson, making it the world's oldest active political party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>SOMANETICS CORP      ITEM 1A RISK FACTORS               An <font color="blue">investment</font> in our <font color="blue"><font color="blue">common shares</font> involves</font> a high degree of risk</td>
    </tr>
    <tr>
      <td>You <font color="blue">should carefully</font> consider the <font color="blue">specific factors described</font> below, together     with  the  <font color="blue">cautionary</font>  statement  under the caption “Forward — Looking     Statements” in Item 7 of this Report and the other information included in     this report, before purchasing our <font color="blue">common shares</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">risks described</font> below     are not the only ones that we face</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks that are not yet known     to  us or that we currently think are <font color="blue">immaterial <font color="blue">could also impair</font></font> our     business,  <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If any of the     following  <font color="blue">risks actually</font> occurs, our business, <font color="blue">financial condition</font> or     results of <font color="blue">operations</font> could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>In such case, the trading     price of our <font color="blue">common shares</font> could decline, and you may lose all or part of     your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Risks Relating to Our Business     Our <font color="blue"><font color="blue">future growth</font> depends on increased market <font color="blue">acceptance</font></font> of our <font color="blue"><font color="blue">INVOS System </font>    </font>in <font color="blue">existing market segments</font> and market <font color="blue">acceptance</font> in <font color="blue">new market segments</font></td>
    </tr>
    <tr>
      <td>Since sales of the INVOS System, including SomaSensors, currently     account for <font color="blue">substantially</font> all of our revenues, our <font color="blue"><font color="blue">future growth</font> will depend</font>     on  the  degree to which our <font color="blue">INVOS System </font>is <font color="blue">accepted by hospitals</font> and     <font color="blue">clinicians</font> in our <font color="blue">existing market segments</font> and in <font color="blue">new market segments</font>, such     as the neonatal ICU, <font color="blue">major surgeries involving diabetic</font> and <font color="blue">elderly patients</font>     and other <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>There are <font color="blue">numerous factors</font> that <font color="blue">could <font color="blue">adversely</font></font>     impact market <font color="blue">acceptance</font> of our INVOS System</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> favorable peer-reviewed <font color="blue">publication</font>     and successful <font color="blue">clinical use</font> of our products for our success</td>
    </tr>
    <tr>
      <td>The INVOS     System has not had extensive <font color="blue">clinical use</font> in the <font color="blue">new market segments</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot assure</font> you that <font color="blue"><font color="blue">additional</font> research papers will</font> be published or that     any <font color="blue">such papers will</font> conclude that the <font color="blue">INVOS System </font>provides information     that is <font color="blue">clinically important</font></td>
    </tr>
    <tr>
      <td>In addition, researchers might publish results     that do not support the <font color="blue">clinical importance</font> of the information <font color="blue">provided by</font>     the <font color="blue">INVOS System </font>or that conclude that another product provides better or     more important information</td>
    </tr>
    <tr>
      <td><font color="blue">Performance </font>problems or <font color="blue">adverse research</font> results     could prevent <font color="blue">acceptance</font> of the product in existing and <font color="blue">new market segments</font>,     <font color="blue">adversely</font>  affect  our  reputation in the <font color="blue">medical community</font>, result in     <font color="blue">unexpected expense</font> and <font color="blue">adversely</font> affect future sales</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">compete with numerous medical equipment companies</font>     for the portions of <font color="blue">hospital budgets allocated</font> to <font color="blue">capital equipment</font> and for     the limited amount of <font color="blue">forehead space on patients</font> to place sensors for all     types of monitoring</td>
    </tr>
    <tr>
      <td>Sales of our <font color="blue">INVOS System </font>might be limited or delayed     because of resistance to major <font color="blue">capital equipment</font> <font color="blue">expenditure</font>s by hospital     <font color="blue">purchasing committees</font></td>
    </tr>
    <tr>
      <td>Even if we are successful in <font color="blue">convincing physicians</font>,     other <font color="blue">medical professionals</font> and hospital <font color="blue">purchasing committees</font> that the     <font color="blue">INVOS System </font>provides valuable benefits, they might be unwilling or unable     to  commit  funds to the purchase of the <font color="blue">INVOS System </font>due to <font color="blue">budgetary</font>     <font color="blue">constraints</font></td>
    </tr>
    <tr>
      <td>Moreover, even if one or two units are sold to a hospital, we     believe that it will take <font color="blue">additional</font> time and experience with the INVOS     System before <font color="blue">additional</font> <font color="blue">medical professionals</font> in the <font color="blue">hospital might</font> be     interested in using the <font color="blue">INVOS System </font>in other procedures or other areas of     the hospital</td>
    </tr>
    <tr>
      <td>Sales of all of our products might be limited because hospitals     might fear that the cost of a new device or <font color="blue">product will lower</font> their profits     because  medical  insurers <font color="blue">generally</font> fix <font color="blue"><font color="blue">reimbursement</font> amounts</font> for the     procedures  in  which  our  products  might be used</td>
    </tr>
    <tr>
      <td>Moreover, medical     <font color="blue">professionals may</font> be reluctant to use our <font color="blue">INVOS System </font>in some new market     segments, <font color="blue">particularly</font> those involving <font color="blue">diagnostic</font> <font color="blue"><font color="blue">application</font>s</font>, unless they     receive <font color="blue">reimbursement</font> from medical insurers for using the system</td>
    </tr>
    <tr>
      <td>Our INVOS     System is not <font color="blue">currently cleared by</font> the FDA for use in the <font color="blue">diagnosis</font> of     disease states</td>
    </tr>
    <tr>
      <td>Additionally, the <font color="blue">INVOS System </font>is not <font color="blue">currently approved</font> for     separate <font color="blue">reimbursement</font>, and we might not be able to obtain <font color="blue">reimbursement</font> for     these uses of our INVOS System</td>
    </tr>
    <tr>
      <td>If the <font color="blue">INVOS System </font>fails to achieve market <font color="blue">acceptance</font> in existing     or  <font color="blue">new market segments</font> or if these <font color="blue">market segments fail</font> to develop as     rapidly  as expected, our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font>  could  be  <font color="blue"><font color="blue">adversely</font> affected</font> and our plan to increase our     <font color="blue">investment</font>s in our <font color="blue">direct sales team</font>, <font color="blue">additional</font> <font color="blue">clinical trials</font> and our     research and <font color="blue"><font color="blue">development</font> team might</font> not produce favorable results</td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________    [50]Table of <font color="blue">Contents       </font>We  are  <font color="blue">dependent</font>  on  our  <font color="blue"><font color="blue">distributor</font>s</font>  and  our  in<font color="blue">dependent</font> sales     <font color="blue"><font color="blue">representative</font> firms</font> for a substantial portion of our sales, and their     failure to sell our <font color="blue">products <font color="blue">adequately</font></font> would <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>We  are <font color="blue">dependent</font> on our <font color="blue"><font color="blue">distributor</font>s</font> to generate all of our     international sales, and on our in<font color="blue">dependent</font> sales <font color="blue"><font color="blue">representative</font> firms</font> for a     substantial  portion  of  our  sales in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In<font color="blue">dependent</font>     <font color="blue"><font color="blue">distributor</font>s</font> or in<font color="blue">dependent</font> sales <font color="blue"><font color="blue">representative</font> firms</font> might fail to commit     the <font color="blue"><font color="blue">necessary</font> resources</font> to market and sell our products to the level of our     expectations, especially as <font color="blue">significant</font> <font color="blue">customer education</font> and long lead     times are typically required to market and sell our <font color="blue">products successfully</font></td>
    </tr>
    <tr>
      <td>If  our <font color="blue"><font color="blue">distributor</font>s</font> or in<font color="blue">dependent</font> sales <font color="blue"><font color="blue">representative</font> firms</font> fail to     market, promote and sell our <font color="blue">products <font color="blue">adequately</font></font>, our business, financial     condition and results of <font color="blue">operations</font> would be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>We might     not be able to engage <font color="blue">additional</font> <font color="blue"><font color="blue">distributor</font>s</font> on a <font color="blue">timely basis</font>, enter into     other third-party marketing <font color="blue">arrangements</font> or retain or replace our existing     <font color="blue"><font color="blue">distributor</font>s</font>, when required</td>
    </tr>
    <tr>
      <td>If we are unable to engage, replace or retain     <font color="blue"><font color="blue">distributor</font>s</font>, our ability to market and sell our <font color="blue">products internationally</font>     could  be  <font color="blue">adversely</font>  affected</td>
    </tr>
    <tr>
      <td>In addition, if any of our <font color="blue">distributor</font>     <font color="blue">arrangements</font> is terminated or <font color="blue">discontinued</font>, we <font color="blue">will likely</font> be <font color="blue">faced with</font>     <font color="blue">increased costs as</font> we attempt to replace these <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>Even if we are     able to engage new <font color="blue"><font color="blue">distributor</font>s</font> or retain <font color="blue">existing ones</font>, they <font color="blue">might incur</font>     <font color="blue">conflicting <font color="blue">obligations</font></font> to sell other companies’ products or they might     distribute other products that <font color="blue">provide greater revenues</font> to them than are     <font color="blue">provided by</font> our products</td>
    </tr>
    <tr>
      <td>Tyco  Healthcare,  part  of  Tyco  International  Ltd,  our     international <font color="blue">distributor</font> in Europe, the Middle East, Africa and Canada for     our  INVOS  System, accounted for 11 percent and 12 percent of our net     revenues  for  fiscal  2005 and for fiscal 2003, respectively</td>
    </tr>
    <tr>
      <td>Edwards     Lifesciences Ltd, formerly Baxter Limited, our international <font color="blue">distributor</font> in     Japan  for our INVOS System, was our <font color="blue">largest customer</font> for fiscal 2004,     although it accounted for less than 10 percent of our <font color="blue">net revenues</font> for     fiscal 2004</td>
    </tr>
    <tr>
      <td>The loss of either of these <font color="blue"><font color="blue">distributor</font>s</font> could have an adverse     effect on our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We plan to increase the number of our <font color="blue"><font color="blue">direct sales team</font> personnel</font>     in the <font color="blue">United States</font> and reduce our dependence on our in<font color="blue">dependent</font> sales     <font color="blue"><font color="blue">representative</font> firms</font></td>
    </tr>
    <tr>
      <td>As a result, we might terminate some of our existing     in<font color="blue">dependent</font>  sales  <font color="blue">representative</font>s,  which  could result in claims by     terminated  sales  <font color="blue"><font color="blue">representative</font> firms</font></td>
    </tr>
    <tr>
      <td>If we are required to pay any     <font color="blue"><font color="blue">significant</font> amounts</font> to terminated sales <font color="blue">representative</font>s, our results of     <font color="blue">operations</font> and <font color="blue">financial condition</font> would be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>We currently <font color="blue">depend on</font> single-source suppliers for <font color="blue">key <font color="blue">components</font></font> of the     INVOS System, and the loss of any of these <font color="blue">suppliers <font color="blue">could harm</font></font> our ability     to <font color="blue">manufacture</font> and sell our products, increase the cost of our <font color="blue">components</font> or     delay our <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>We  are <font color="blue">dependent</font> on various suppliers for <font color="blue">manufacturing</font> the     <font color="blue">components</font> for our INVOS System</td>
    </tr>
    <tr>
      <td>Although we believe that most <font color="blue">components</font>     are <font color="blue">generally</font> available from several potential suppliers, we <font color="blue">depend on</font> one     supplier  for one of our <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>We are not aware of any validated     <font color="blue">alternative supplier</font> for this component, although we are currently in the     process of validating in <font color="blue">accordance with</font> FDA <font color="blue">requirements</font> a <font color="blue">second source</font> of     supply</td>
    </tr>
    <tr>
      <td>Moreover,  we  <font color="blue">typically use one supplier</font> for custom-designed     <font color="blue">components</font>, including the unit enclosure, the <font color="blue">printed circuit boards</font>, other     mechanical <font color="blue">components</font> and the SomaSensor</td>
    </tr>
    <tr>
      <td><font color="blue">SomaSensors </font>represented 75 percent     of  our  <font color="blue">net revenues</font> in fiscal 2005</td>
    </tr>
    <tr>
      <td>Engaging <font color="blue">additional</font> or replacing     existing  suppliers  of  custom-designed <font color="blue">components</font> is costly and time     consuming</td>
    </tr>
    <tr>
      <td>We estimate that it would require <font color="blue">approximately four</font> to five     months  to  change  <font color="blue">SomaSensor </font>suppliers</td>
    </tr>
    <tr>
      <td>We do not intend to maintain     <font color="blue"><font color="blue">significant</font> inventories</font> of <font color="blue">components</font>, other than an approximate six-month     supply of the one component for which we currently have <font color="blue">no alternative</font>     supplier</td>
    </tr>
    <tr>
      <td>If we fail to obtain custom-designed <font color="blue">components</font> from our sole     suppliers, if we lose any of our <font color="blue">present suppliers</font> and <font color="blue">cannot replace them</font>     on a <font color="blue">timely basis</font> when <font color="blue">necessary</font>, if there is an <font color="blue">interruption</font> of production     at one or more of our suppliers, or if any supplier is <font color="blue">otherwise unable</font> or     unwilling to meet our <font color="blue">requirements</font> at current prices or at all, our ability     to <font color="blue">manufacture</font> and sell our <font color="blue">products would</font> be impaired or we might have to     pay  higher  prices for our <font color="blue">components</font> or our <font color="blue">clinical trials</font> could be     delayed</td>
    </tr>
    <tr>
      <td>In addition, because we do not have long-term <font color="blue"><font color="blue">agreement</font>s</font> with our     suppliers, we might be subject to <font color="blue">unexpected price increases which might</font>     <font color="blue">adversely</font> affect our <font color="blue">profit margins</font></td>
    </tr>
    <tr>
      <td>In addition, we do not have <font color="blue">direct control over</font> the <font color="blue">activities</font> of     our suppliers and are <font color="blue">dependent</font> on them for quality control, capacity,     <font color="blue">processing <font color="blue">technologies</font></font> and, in required cases, compliance with FDA Quality     System Regulation <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in managing our     suppliers, our business could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________    [51]Table of <font color="blue">Contents       </font>We may become subject to <font color="blue">competition</font> which may <font color="blue">adversely</font> affect us</td>
    </tr>
    <tr>
      <td>We believe that the markets for cerebral and <font color="blue">somatic oximetry</font>     <font color="blue"><font color="blue">products may</font> become highly <font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, we believe     there is <font color="blue">currently only one</font> other <font color="blue">company with</font> FDA clearance to sell a     <font color="blue">cerebral oximeter</font></td>
    </tr>
    <tr>
      <td><font color="blue">In December </font>2005, CAS Medical Systems, Inc</td>
    </tr>
    <tr>
      <td>announced     that it received 510(k) clearance to market a <font color="blue">cerebral oximeter</font> for the     adult market, with plans to launch the product in late 2006</td>
    </tr>
    <tr>
      <td>Outside the     <font color="blue">United States</font>, several Japanese <font color="blue">manufacture</font>rs offer <font color="blue">competitive</font> products for     sale in that country and primarily for research in other parts of the world,     but, to our knowledge, as of yet, none has pursued FDA clearance to market     its product in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We are aware that several companies and     individuals are engaged in the research and <font color="blue">development</font> of non-invasive     <font color="blue">cerebral oximeter</font>s, and we believe that there are several other potential     <font color="blue">entrants into</font> the market</td>
    </tr>
    <tr>
      <td>Other companies have FDA clearance to market     <font color="blue">somatic oximeters</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>might cause our sales     cycle  to  lengthen  to  the extent that customers take longer to make     <font color="blue">purchasing decisions</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font><font color="blue"><font color="blue">might also</font> reduce</font> our gross margins and     market share and <font color="blue">prevent us from</font> achieving <font color="blue">further market penetration</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>might be more <font color="blue">successful than</font> we are in obtaining FDA clearance     with broader claims in their labeling or more <font color="blue">successful than</font> we are in     <font color="blue">manufacturing</font> and marketing their products and may be able to take advantage     of  the  <font color="blue">significant</font>  time and effort we have invested to <font color="blue">gain medical</font>     <font color="blue">acceptance</font> of <font color="blue">cerebral oximetry</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also compete with companies</font> that have longer operating histories, more     <font color="blue">established products</font> and <font color="blue">greater <font color="blue">resources than</font></font> we do for, among other     things, forehead monitoring space, limited <font color="blue">hospital capital budgets</font> and     <font color="blue">alternative products</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">medical products industry</font> is <font color="blue">characterized by</font> extensive     research  and  <font color="blue">development</font>  and <font color="blue">intense <font color="blue">competition</font></font> in an <font color="blue">increasingly</font>     cost-conscious  <font color="blue">environment</font></td>
    </tr>
    <tr>
      <td>Some of these potential <font color="blue">competitors</font> have     well-established  <font color="blue">reputations</font>,  customer  <font color="blue">relationships</font> and marketing,     <font color="blue">distribution</font> and service networks</td>
    </tr>
    <tr>
      <td>Some of them have <font color="blue">substantially</font> longer     histories in the <font color="blue">medical products industry</font>, larger product lines and greater     financial, technical, <font color="blue">manufacturing</font>, research and <font color="blue">development</font> and <font color="blue">management</font>     <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td>Many of these potential <font color="blue">competitors</font> have long-term     product supply <font color="blue">relationships</font> with our <font color="blue">potential customer</font>s</td>
    </tr>
    <tr>
      <td>These potential     <font color="blue">competitors</font> might be able to use their resources, <font color="blue">reputations</font> and ability to     leverage  existing  customer  <font color="blue">relationships</font> to give them a <font color="blue">competitive</font>     <font color="blue">advantage over us</font>, including in <font color="blue">securing forehead sensor space</font> for their     products and dollars from hospital <font color="blue">capital equipment</font> budgets to purchase     their products</td>
    </tr>
    <tr>
      <td>They <font color="blue">might also</font> succeed in developing products that are at     least  as reliable and <font color="blue"><font color="blue">effective</font> as</font> our products, that make <font color="blue">additional</font>     <font color="blue">measurements</font>,  that  are <font color="blue">less costly than</font> our products or that provide     <font color="blue">alternatives</font> to our products</td>
    </tr>
    <tr>
      <td>If we fail to manage our <font color="blue">growth <font color="blue"><font color="blue">effective</font>ly</font></font>, our business and operating     results could be harmed</td>
    </tr>
    <tr>
      <td>If we experience growth in our business, our <font color="blue">growth could</font> place a     <font color="blue">significant</font> strain on our <font color="blue">management</font>, customer service, <font color="blue">operations</font>, sales     and <font color="blue">administrative personnel</font> and other resources</td>
    </tr>
    <tr>
      <td>To serve the needs of our     existing and <font color="blue">future customers</font>, we will be required to train, motivate and     <font color="blue">manage <font color="blue">qualified employees</font></font></td>
    </tr>
    <tr>
      <td>We have incurred and <font color="blue">will continue</font> to incur     <font color="blue">significant</font> costs to retain qualified <font color="blue">management</font>, sales and marketing,     engineering, production, <font color="blue">manufacturing</font> and <font color="blue">administrative personnel</font>, as well     as expenses for marketing and promotional <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Our ability to manage     our planned <font color="blue">growth depends upon</font> our success in expanding our operating,     <font color="blue">management</font> and information and financial systems, which might <font color="blue">significant</font>ly     increase our operating expenses</td>
    </tr>
    <tr>
      <td>We expect to continue to invest substantial resources to develop a     smaller <font color="blue">SomaSensor </font>for use with newborns, product-line extension of the     <font color="blue">INVOS System </font>for monitoring non-brain tissues and other advances to the     design  and  performance  features  of the INVOS System, including the     disposable SomaSensor</td>
    </tr>
    <tr>
      <td>New products require extensive testing and <font color="blue">regulatory</font>     clearance before they can be marketed, and substantial <font color="blue">customer education</font>     <font color="blue">concerning</font> the product’s use, advantages and <font color="blue"><font color="blue">effective</font>ness</font></td>
    </tr>
    <tr>
      <td>We might not be     able to develop <font color="blue"><font color="blue">commercially</font> viable products</font></td>
    </tr>
    <tr>
      <td>We might not be able to manage     <font color="blue"><font color="blue">effective</font>ly</font>  our <font color="blue">future growth</font>, and if we fail to do so, our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font> would be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________    [52]Table of <font color="blue">Contents       </font>Patients might assert <font color="blue">product liability</font> claims <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Because we test, market and sell a <font color="blue">patient monitoring</font> device and a     heart patch, patients might assert <font color="blue">product liability</font> claims <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">INVOS System </font>is used in operating rooms and other <font color="blue">critical care hospital</font>     units  <font color="blue">with patients</font> who might be <font color="blue">seriously ill</font> or might be undergoing     <font color="blue"><font color="blue">dangerous procedure</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">The <font color="blue"><font color="blue">CorRestore </font>Patch </font></font>is used on <font color="blue">seriously ill</font> patients     undergoing a <font color="blue">dangerous procedure</font></td>
    </tr>
    <tr>
      <td>On occasion, patients on whom the INVOS     System is being used, or in whom a <font color="blue"><font color="blue">CorRestore </font>Patch </font>is implanted, may be     injured or die as a result of their <font color="blue">medical treatment</font> or condition</td>
    </tr>
    <tr>
      <td>We might     be sued because of <font color="blue">such injury</font> or death, and <font color="blue">regardless</font> of whether we are     ultimately determined to be liable or our products are determined to be     defective and a <font color="blue">contributing</font> factor in <font color="blue">such injury</font> or death, we <font color="blue">might incur</font>     <font color="blue">significant</font> legal expenses not <font color="blue">covered by insurance</font></td>
    </tr>
    <tr>
      <td>In addition, product     <font color="blue">liability <font color="blue">litigation</font> could damage</font> our reputation and impair our ability to     market our products, <font color="blue">regardless</font> of the outcome</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font><font color="blue">could also impair</font>     our ability to retain <font color="blue">product liability</font> insurance or make our insurance more     expensive</td>
    </tr>
    <tr>
      <td>We have <font color="blue">product liability</font> insurance with a <font color="blue">liability limit</font> of     dlra5cmam000cmam000</td>
    </tr>
    <tr>
      <td>This insurance is costly and <font color="blue">even though</font> it has been obtained,     we  might not be able to retain it</td>
    </tr>
    <tr>
      <td>Even if we are able to retain this     insurance, it might not be sufficient to <font color="blue">protect us</font> in the event of a major     defect in the <font color="blue">INVOS System </font>or the <font color="blue">CorRestore </font>Patch</td>
    </tr>
    <tr>
      <td>If we are subject to an     uninsured or in<font color="blue">adequately</font> insured <font color="blue">product liability</font> claim <font color="blue">based on</font> the     performance of the <font color="blue">INVOS System </font>or the <font color="blue">CorRestore </font>Patch, our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font> could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>If  we  fail  to  obtain  and  maintain  <font color="blue">necessary</font>  US Food and Drug     Administration <font color="blue">clearances</font> for our products and <font color="blue"><font color="blue">indication</font>s</font> or if <font color="blue">clearances</font>     for <font color="blue">future products</font> and <font color="blue"><font color="blue">indication</font>s</font> are delayed or not issued, our business     would be harmed</td>
    </tr>
    <tr>
      <td>Our products are <font color="blue">classified as medical devices</font> and are subject to     extensive regulation in the <font color="blue">United States</font> by the FDA and other federal,     state and <font color="blue">local <font color="blue">authorities</font></font></td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> relate to <font color="blue">manufacturing</font>,     labeling,  sale,  promotion, <font color="blue">distribution</font>, importing and exporting and     shipping of our products</td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, before we can market a new     medical device, or a new use of, or claim for, an <font color="blue">existing product such as</font>     the INVOS System, we must first receive either 510(k) clearance or premarket     <font color="blue">approval from</font> the FDA, unless an <font color="blue">exemption applies</font></td>
    </tr>
    <tr>
      <td>The FDA’s 510(k) clearance process usually     takes from three to six months, but it can <font color="blue">last longer</font></td>
    </tr>
    <tr>
      <td>The process of     obtaining <font color="blue">premarket approval</font> is much more costly and <font color="blue">uncertain than</font> the     510(k) clearance process</td>
    </tr>
    <tr>
      <td>It <font color="blue">generally</font> takes from one to <font color="blue">three years</font>, or     even longer, from the time the <font color="blue">premarket approval</font> <font color="blue">application</font> is submitted     to the FDA until an approval is obtained</td>
    </tr>
    <tr>
      <td>In order to obtain <font color="blue">premarket approval</font> and, in some cases, a 510(k)     clearance, a product sponsor must conduct well-controlled <font color="blue">clinical trials</font>     designed to test the safety and <font color="blue"><font color="blue">effective</font>ness</font> of the product</td>
    </tr>
    <tr>
      <td><font color="blue">Conducting     </font><font color="blue">clinical trials</font> <font color="blue">generally</font> entails a long, expensive and <font color="blue">uncertain process</font>     that is subject to delays and <font color="blue">failure at</font> any stage</td>
    </tr>
    <tr>
      <td>The data obtained from     <font color="blue">clinical trials</font> may be inadequate to <font color="blue">support approval</font> or clearance of a     submission</td>
    </tr>
    <tr>
      <td>In addition, the occurrence of <font color="blue">unexpected findings</font> in <font color="blue">connection</font>     with <font color="blue">clinical trials</font> may prevent or delay obtaining approval or clearance</td>
    </tr>
    <tr>
      <td>If  we  conduct  <font color="blue">clinical trials</font>, they may be delayed or halted, or be     inadequate to <font color="blue">support approval</font> or clearance</td>
    </tr>
    <tr>
      <td>Medical <font color="blue">devices may</font> be <font color="blue">marketed only</font> for the <font color="blue"><font color="blue">indication</font>s</font> for which     they  are  approved  or  cleared</td>
    </tr>
    <tr>
      <td>The FDA may fail to approve or clear     <font color="blue"><font color="blue">indication</font>s</font>   that   are   <font color="blue">necessary</font>   or   desirable  for  successful     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Indeed, the FDA may refuse our requests for 510(k)     clearance  or <font color="blue">premarket approval</font> of <font color="blue">new products</font>, <font color="blue">new <font color="blue">intended use</font>s</font> or     <font color="blue">modifications</font> to <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">clearances</font> can be revoked if safety     or <font color="blue"><font color="blue">effective</font>ness</font> problems develop</td>
    </tr>
    <tr>
      <td>The FDA might require us to obtain a new clearance to label or promote more     actively the <font color="blue">INVOS System </font>for specific patient subgroups, such as <font color="blue">diabetics</font>;     if  we  fail  to obtain such <font color="blue">clearances</font>, our sales and revenues may be     <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">INVOS System </font>510(k) clearance states that the prospective     <font color="blue">clinical value</font> of the <font color="blue">INVOS System </font>has not <font color="blue">been <font color="blue">demonstrate</font>d</font> in patients     <font color="blue">with specific disease</font> states</td>
    </tr>
    <tr>
      <td>If we wish to label or promote more actively     the <font color="blue">INVOS System </font>for specific types of patients, such as <font color="blue">diabetics</font>, <font color="blue">the FDA     </font>may require us to obtain a new 510(k) clearance and <font color="blue"><font color="blue">would likely</font> carefully</font>     scrutinize the <font color="blue">data support</font> for any such claim</td>
    </tr>
    <tr>
      <td>The FDA may also determine     that  our <font color="blue">current promotion</font> of the <font color="blue">INVOS System </font>as suitable for use in     <font color="blue">diabetics</font> constitutes promotion for an <font color="blue">unapproved use</font> and                                         23       _________________________________________________________________    [53]Table of <font color="blue">Contents       </font>may take <font color="blue">regulatory</font> action <font color="blue">against us</font> and require us to cease and desist     <font color="blue">from such promotion until</font> a new clearance or approval is obtained</td>
    </tr>
    <tr>
      <td>We cannot     assure you that the FDA would grant <font color="blue">additional</font> 510(k) <font color="blue">clearances</font> in a timely     fashion, or at all, or that the FDA would not require us to undertake the     more burdensome <font color="blue">premarket approval</font> process as a <font color="blue">prerequisite</font> for marketing     the <font color="blue">INVOS System </font>with this type of claim</td>
    </tr>
    <tr>
      <td>Any of the above <font color="blue">could delay</font> our     ability to market and <font color="blue">sell <font color="blue">new products</font></font> or to promote the <font color="blue">INVOS System </font>for     specific patient subgroups such as <font color="blue">diabetics</font> and would thereby have an     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>After clearance or approval of our products, we are subject to continuing     <font color="blue">regulation by</font> the FDA, and if we fail to <font color="blue">comply with</font> FDA <font color="blue">regulations</font>, our     business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>Even after clearance or approval of a product, we are subject to     continuing  <font color="blue">regulation by</font> the FDA, including the <font color="blue">requirements</font> that our     <font color="blue">facility</font>  be registered and our <font color="blue">devices listed with</font> the agency</td>
    </tr>
    <tr>
      <td>We are     subject to <font color="blue">Medical Device Reporting </font><font color="blue">regulations</font>, which require us to report     to the FDA if our <font color="blue">products may</font> have caused or contributed to a death or     <font color="blue">serious injury</font> or <font color="blue">malfunction</font> in a way that <font color="blue">would likely</font> cause or contribute     to a death or <font color="blue">serious injury</font> if the <font color="blue">malfunction</font> were to recur</td>
    </tr>
    <tr>
      <td>We must     report <font color="blue">corrections</font> and removals to the FDA where the correction or removal     was initiated to reduce a risk to health posed by the device or to remedy a     violation of the Federal Food, Drug, and Cosmetic Act caused by the device     that <font color="blue">may present</font> a risk to health, and maintain records of other <font color="blue">corrections</font>     or removals</td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">closely regulates promotion</font> and <font color="blue">advertising</font>, and our     promotional and <font color="blue">advertising</font> <font color="blue">activities</font> could come under scrutiny</td>
    </tr>
    <tr>
      <td>If <font color="blue">the FDA     </font>objects to our promotional and <font color="blue">advertising</font> <font color="blue">activities</font> or finds that we     failed to submit reports under the <font color="blue">Medical Device Reporting </font><font color="blue">regulations</font>, for     example, the FDA may allege our <font color="blue">activities</font> resulted in violations</td>
    </tr>
    <tr>
      <td>The FDA and state <font color="blue">authorities</font> have broad <font color="blue">enforcement</font> powers</td>
    </tr>
    <tr>
      <td>Our     failure to <font color="blue">comply with</font> applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> could result in     <font color="blue">enforcement</font> action by the FDA or state agencies, which may include any of     the <font color="blue">following sanctions</font>:       •   untitled letters, warning letters, fines, injunctions, consent decrees     and <font color="blue">civil penalties</font>;         •   repair, replacement, refunds, recall or seizure of our products;         •   operating <font color="blue">restrictions</font> or <font color="blue">partial suspension</font> or <font color="blue">total shutdown</font> of     production;         •   refusing or delaying our requests for 510(k) clearance or premarket     approval of <font color="blue">new products</font> or <font color="blue">new <font color="blue">intended use</font>s</font>;         •   withdrawing 510(k) clearance or <font color="blue">premarket approval</font>s that have already     <font color="blue">been granted</font>; and         •   <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>If any of these events were to occur, they <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>We have modified some of our <font color="blue">products without</font> FDA clearance</td>
    </tr>
    <tr>
      <td>The FDA could     <font color="blue">retroactively</font> determine that the <font color="blue">modifications</font> were improper and require us     to <font color="blue">stop marketing</font> and recall the <font color="blue">modified products</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">modifications</font> to one of our FDA-cleared devices that could     <font color="blue">significant</font>ly affect its safety or <font color="blue"><font color="blue">effective</font>ness</font>, or that <font color="blue">would constitute</font> a     major change in its <font color="blue">intended use</font>, requires a new 510(k) clearance or a     <font color="blue">premarket approval</font></td>
    </tr>
    <tr>
      <td>We may be required to submit extensive pre-clinical and     <font color="blue">clinical data depending on</font> the nature of the changes</td>
    </tr>
    <tr>
      <td>We may not be able to     obtain <font color="blue">additional</font> 510(k) <font color="blue">clearances</font> or <font color="blue">premarket approval</font>s for <font color="blue">modifications</font>     to,  or  <font color="blue">additional</font> <font color="blue"><font color="blue">indication</font>s</font> for, our <font color="blue">existing products</font> in a timely     fashion, or at all</td>
    </tr>
    <tr>
      <td>Delays in obtaining future <font color="blue">clearances</font> or approvals would     <font color="blue">adversely</font> affect our ability to introduce new or enhanced products in a     timely manner, which in turn would harm our revenue and operating results</td>
    </tr>
    <tr>
      <td>We have made <font color="blue">modifications</font> to our devices in the past, such as changes to     the SomaSensor, and may make <font color="blue">additional</font> <font color="blue">modifications</font> in the future that we     believe do not or will not require <font color="blue">additional</font> <font color="blue">clearances</font> or approvals</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>disagrees, and requires new <font color="blue">clearances</font> or approvals for     the <font color="blue">modifications</font>, we may be required to recall and to <font color="blue">stop marketing</font> the     modified devices, which <font color="blue">could harm</font> our operating results and require us to     redesign our products</td>
    </tr>
    <tr>
      <td>24       _________________________________________________________________    [54]Table of <font color="blue">Contents       </font>If  we  fail  to  <font color="blue">comply with</font> the FDA’s Quality System Regulation, our     <font color="blue">manufacturing</font> <font color="blue">operations</font> could be halted, and our business <font color="blue">would suffer</font></td>
    </tr>
    <tr>
      <td>We are currently required to <font color="blue">demonstrate</font> and maintain compliance     with the FDA’s Quality System Regulation, or QSR The QSR is a complex     <font color="blue">regulatory</font> scheme that covers the methods and <font color="blue">documentation</font> of the design,     testing, control, <font color="blue">manufacturing</font>, labeling, quality assurance, packaging,     storage and shipping of our products</td>
    </tr>
    <tr>
      <td>The FDA enforces the QSR through     <font color="blue">periodic unannounced inspections</font></td>
    </tr>
    <tr>
      <td>We have been, and anticipate in the future     being, subject to <font color="blue">such inspections</font></td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">comply with</font> the QSR or to     take satisfactory <font color="blue">corrective action</font> in response to an adverse QSR inspection     could result in <font color="blue">enforcement</font> actions, including a <font color="blue">public warning letter</font>, a     shutdown of or <font color="blue">restrictions</font> on our <font color="blue">manufacturing</font> <font color="blue">operations</font>, delays in     approving or clearing a product, refusal to permit the import or export of     our products, a recall or seizure of our products, fines, injunctions, civil     or <font color="blue">criminal penalties</font>, or other sanctions, any of <font color="blue">which could</font> cause our     business and operating results to suffer</td>
    </tr>
    <tr>
      <td>Failure to obtain or maintain <font color="blue">regulatory</font> approval in foreign <font color="blue">jurisdictions</font>     would <font color="blue">prevent us from</font> marketing our products abroad</td>
    </tr>
    <tr>
      <td>We market our products through <font color="blue"><font color="blue">distributor</font>s</font> in <font color="blue">foreign markets</font></td>
    </tr>
    <tr>
      <td>In     order  to market our products in the <font color="blue">European Community </font>and many other     foreign <font color="blue">jurisdictions</font>, we must obtain separate <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>We     depend  on  our  <font color="blue"><font color="blue">distributor</font>s</font>  to obtain and maintain certain of these     <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>The <font color="blue">approval procedure varies among countries</font> and can     involve <font color="blue">additional</font> <font color="blue">requirements</font> and testing, and the time required to obtain     <font color="blue">approval may differ from</font> that required to obtain FDA clearance</td>
    </tr>
    <tr>
      <td>The foreign     <font color="blue">regulatory</font> approval process may include all of the risks associated with     obtaining FDA clearance in addition to other risks</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">distributor</font>s</font> might     not be able to obtain or maintain <font color="blue">foreign approvals on</font> a <font color="blue">timely basis</font> or at     all</td>
    </tr>
    <tr>
      <td><font color="blue">Clearance </font>by the FDA does not ensure approval by <font color="blue">regulatory</font> <font color="blue">authorities</font>     in other countries, and approval by one foreign <font color="blue">regulatory</font> authority does     not ensure approval by <font color="blue">regulatory</font> <font color="blue">authorities</font> in other <font color="blue">foreign countries</font> or     approval or <font color="blue">clearance by</font> the <font color="blue">FDA Failure </font>to obtain or maintain <font color="blue">regulatory</font>     approval  in foreign <font color="blue">jurisdictions</font> would <font color="blue">prevent us from</font> marketing our     products abroad</td>
    </tr>
    <tr>
      <td>Federal <font color="blue">regulatory</font> reforms may <font color="blue">adversely</font> affect our ability to sell our     <font color="blue">products profitably</font></td>
    </tr>
    <tr>
      <td>From  time to time, <font color="blue">legislation</font> is drafted and introduced in     <font color="blue">Congress </font>that could <font color="blue">significant</font>ly change the <font color="blue">statutory provisions governing</font>     clearance or approval, <font color="blue">manufacture</font> and marketing of a device</td>
    </tr>
    <tr>
      <td>In addition,     FDA <font color="blue">regulations</font> and guidance are <font color="blue">often revised</font> or <font color="blue">reinterpreted by</font> the     agency in ways that may <font color="blue">significant</font>ly affect our business and our products</td>
    </tr>
    <tr>
      <td>We  cannot  <font color="blue">predict whether legislative</font> changes will be enacted or FDA     <font color="blue">regulations</font>, guidance or <font color="blue"><font color="blue">interpretation</font>s</font> changed, and what the impact of     such changes, if any, may be</td>
    </tr>
    <tr>
      <td>Changes in our actual or estimated future <font color="blue">taxable income could</font> change the     value of our deferred tax asset, <font color="blue">potentially</font> resulting in a decrease in net     income, which <font color="blue">could <font color="blue">adversely</font></font> affect the price of our <font color="blue">common shares</font></td>
    </tr>
    <tr>
      <td>We have recognized <font color="blue">deferred tax assets</font> relating to the expected     <font color="blue">future benefits</font> of our net operating <font color="blue">loss carryforwards</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">assessment</font> of     our <font color="blue">deferred tax assets</font>, and the reversal of part of our <font color="blue">valuation allowance</font>     relating to those assets in fiscal 2005 and 2004, included assuming that our     <font color="blue">net revenues</font> and pre-tax income will grow in <font color="blue">future years consistent with</font>     the growth guidance given for fiscal 2006 and making allowance for the     <font color="blue">uncertainties</font> surrounding, among things, our <font color="blue">future rate</font> of growth in net     revenues, the rate of adoption of our products in the marketplace, and the     potential for <font color="blue">competition</font> to enter the marketplace</td>
    </tr>
    <tr>
      <td>Given the <font color="blue">assumptions</font>     inherent in our financial plans, it is possible to calculate a <font color="blue">different</font>     value for our <font color="blue">deferred tax assets</font> by changing one or more of the variables     in our <font color="blue">assessment</font></td>
    </tr>
    <tr>
      <td>In addition, changes in our actual or estimated future     <font color="blue">taxable income could</font> change the value of our deferred tax asset, <font color="blue">potentially</font>     resulting in a decrease in net income, which <font color="blue">could <font color="blue">adversely</font></font> affect the     price of our <font color="blue">common shares</font></td>
    </tr>
    <tr>
      <td>New <font color="blue">stock option <font color="blue">accounting rules</font> will increase</font> our reported expenses, which     <font color="blue">could <font color="blue">adversely</font></font> affect the price of our <font color="blue">common shares</font></td>
    </tr>
    <tr>
      <td><font color="blue">Effective December </font>1, 2005, we became subject to <font color="blue">new stock option</font>     <font color="blue">accounting rules</font> that require that <font color="blue"><font color="blue">compensation</font> costs</font> related to share-based     <font color="blue">payment transactions</font>, including <font color="blue">stock options</font>, stock <font color="blue">appreciation</font> rights                                         25       _________________________________________________________________    [55]Table of <font color="blue">Contents       </font>and <font color="blue">restricted stock</font>, be recognized in our financial statements</td>
    </tr>
    <tr>
      <td>Previously,     we accounted for stock-based <font color="blue">compensation</font> of employees using the intrinsic     value method, which resulted in <font color="blue">no <font color="blue">compensation</font> expense charged against</font>     income for <font color="blue">stock option grants</font> to employees for fiscal 2005, 2004 or 2003</td>
    </tr>
    <tr>
      <td>In addition, in November 2005, we <font color="blue">accelerated</font> the vesting of all unvested     <font color="blue">stock options</font> to <font color="blue">eliminate <font color="blue">compensation</font> expense</font> that we <font color="blue">would otherwise</font> have     recognized in our results of <font color="blue">operations</font> after the adoption of the new stock     option <font color="blue">accounting rules</font> when those <font color="blue">options would</font> have <font color="blue">otherwise vested</font></td>
    </tr>
    <tr>
      <td>Future grants of options, however, will require us to recognize <font color="blue">compensation</font>     expense in our income statement, increasing our reported expenses for the     same  <font color="blue">activities</font>, which <font color="blue">could <font color="blue">adversely</font></font> affect the price of our common     shares</td>
    </tr>
    <tr>
      <td>The <font color="blue">lengthy sales cycle</font> for the <font color="blue">INVOS System </font>could cause <font color="blue">variability</font> in our     operating results</td>
    </tr>
    <tr>
      <td>The decision-making process for our <font color="blue">INVOS System </font>customers is     <font color="blue">often complex</font> and time-consuming</td>
    </tr>
    <tr>
      <td>We believe the <font color="blue">period between initial</font>     <font color="blue">discussions</font>  with  a <font color="blue">potential customer</font> and a sale of even one unit is     <font color="blue">typically approximately six</font> to <font color="blue">nine months</font></td>
    </tr>
    <tr>
      <td>The process can be <font color="blue">delayed as</font> a     result of <font color="blue">hospital capital budgeting procedures</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">delays could</font> have an     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font> and cause <font color="blue">variability</font> in our operating results <font color="blue">from quarter</font> to     quarter, <font color="blue">which could</font> cause <font color="blue">fluctuations</font> in the <font color="blue">trading price</font> of our common     shares</td>
    </tr>
    <tr>
      <td>If we are unable to obtain or maintain <font color="blue"><font color="blue">intellectual property</font> rights</font> relating     to our <font color="blue">technology</font> and products, the <font color="blue">commercial value</font> of our <font color="blue">technology</font> and     <font color="blue">products will</font> be <font color="blue"><font color="blue">adversely</font> affected</font> and our <font color="blue">competitive</font> position could be     harmed</td>
    </tr>
    <tr>
      <td>Our  success and ability to <font color="blue">compete depends</font> in part upon our     ability to obtain protection in the <font color="blue">United States</font> and other countries for     our products by establishing and maintaining <font color="blue"><font color="blue">intellectual property</font> rights</font>     relating to or <font color="blue"><font color="blue">incorporated</font> into</font> our <font color="blue">technology</font> and products</td>
    </tr>
    <tr>
      <td>We own or     license a variety of patents and patent <font color="blue"><font color="blue">application</font>s</font> in the <font color="blue">United States</font>     and  <font color="blue">corresponding</font>  patents and patent <font color="blue"><font color="blue">application</font>s</font> in certain foreign     <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>Pending and future patent <font color="blue"><font color="blue">application</font>s</font> owned or licensed by     us may not issue as patents or, if issued, may not issue in a form that will     be  <font color="blue">commercially</font>  <font color="blue">advantageous</font>  to  us</td>
    </tr>
    <tr>
      <td>Even if issued, <font color="blue">patents may</font> be     challenged, narrowed, invalidated or circumvented, <font color="blue">which could</font> limit our     ability to stop <font color="blue">competitors</font> from marketing similar products or limit the     length  of  term of <font color="blue">patent protection</font> we may have for our products</td>
    </tr>
    <tr>
      <td>In     addition, <font color="blue">already issued</font> patents owned or <font color="blue">licensed by us may</font> not be valid or     enforceable</td>
    </tr>
    <tr>
      <td>Further, even if valid and enforceable, these <font color="blue">already issued</font>     <font color="blue">patents may</font> not be <font color="blue">sufficiently broad</font> to <font color="blue">prevent others from marketing</font>     <font color="blue">competitive</font> products, despite our <font color="blue">patent rights</font></td>
    </tr>
    <tr>
      <td>Changes in either patent     laws or in <font color="blue"><font color="blue">interpretation</font>s</font> of <font color="blue">patent laws</font> in the <font color="blue">United States</font> and other     <font color="blue">countries may diminish</font> the value of our <font color="blue">intellectual property</font> or narrow the     scope of our <font color="blue">patent protection</font></td>
    </tr>
    <tr>
      <td>For example, one of our <font color="blue">significant</font> patents is the subject of a     <font color="blue">reissue proceeding</font> in the <font color="blue">US Patent and Trademark Office</font></td>
    </tr>
    <tr>
      <td>Our reissue     <font color="blue">application</font> was filed for the <font color="blue">sole purpose</font> of seeking to <font color="blue">broaden certain</font>     claims</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the outcome of this proceeding, which may result     in some or all of the claims being broadened, narrowed or rejected</td>
    </tr>
    <tr>
      <td><font color="blue">Another     </font>of our <font color="blue">patents may</font> be expired for ultimately claiming priority to a patent     that was filed more than 20 years ago</td>
    </tr>
    <tr>
      <td>We believe that this patent does not     have a claim of priority that <font color="blue">extends back</font> for more than 20 years, and that     the patent is <font color="blue">still extant</font> and will expire on March 29, 2009</td>
    </tr>
    <tr>
      <td>However, there     is a risk that a <font color="blue">court might find</font> that the <font color="blue">earliest <font color="blue">effective</font> <font color="blue">filing date</font></font>     for this patent is more than 20 years ago, and rule that this patent is     expired and unenforceable</td>
    </tr>
    <tr>
      <td>The validity of our patent claims depends, in part, on whether     <font color="blue">prior art references</font> disclosed or rendered obvious our <font color="blue"><font color="blue">inventions</font> as</font> of the     <font color="blue">filing date</font> of our patent <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>We may not have identified all prior     art, such as US and foreign patents or published <font color="blue"><font color="blue">application</font>s</font> or published     scientific literature, that <font color="blue">could <font color="blue">adversely</font></font> affect the validity of our     <font color="blue">issued patents</font> or the <font color="blue">patentability</font> of our pending patent <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>For     example,  patent  <font color="blue"><font color="blue">application</font>s</font>  in the <font color="blue">United States</font> are maintained in     confidence for up to 18 months after their filing</td>
    </tr>
    <tr>
      <td>In some cases, however,     patent <font color="blue"><font color="blue">application</font>s</font> remain confidential in the US Patent and Trademark     Office  for the entire time prior to <font color="blue">issuance as</font> a US patent</td>
    </tr>
    <tr>
      <td><font color="blue">Patent     </font><font color="blue"><font color="blue">application</font>s</font> filed in <font color="blue">countries outside</font> the <font color="blue">United States</font> are also not     typically published until at least 18 months from their first <font color="blue">filing date</font></td>
    </tr>
    <tr>
      <td>Similarly, <font color="blue">publication</font> of <font color="blue">discoveries</font> in the scientific or <font color="blue">patent literature</font>     often lags behind actual <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td>26       _________________________________________________________________    [56]Table of <font color="blue">Contents       </font>          We <font color="blue">may initiate <font color="blue">litigation</font></font> to enforce our <font color="blue">patent rights</font>, which may     prompt our <font color="blue">adversaries</font> in <font color="blue">such <font color="blue">litigation</font></font> to challenge the validity, scope     or <font color="blue">enforceability</font> of our patents</td>
    </tr>
    <tr>
      <td>If a court decides that our patents are     not valid, not enforceable or of a limited scope, we will not have the right     to <font color="blue">stop others from using</font> our <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>The outcome of <font color="blue">litigation</font> to enforce our <font color="blue">patent rights</font> is subject     to substantial <font color="blue">uncertainties</font>, especially in medical device-related patent     cases that may, for example, turn on the <font color="blue">interpretation</font> of patent claim     language  by the <font color="blue">court which may</font> not be to our advantage, and also the     testimony of <font color="blue">experts as</font> to <font color="blue">technical facts upon which experts may reasonably</font>     disagree</td>
    </tr>
    <tr>
      <td>Our involvement in such <font color="blue">intellectual property</font> <font color="blue">litigation</font> could     result in <font color="blue">significant</font> expense</td>
    </tr>
    <tr>
      <td>We <font color="blue">also cannot</font> be certain that we were the first to invent, or the     first  to  file patent <font color="blue"><font color="blue">application</font>s</font> relating to, our <font color="blue">cerebral oximeter</font>     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>In the event that a <font color="blue">third party</font> has also filed a US patent     <font color="blue">application</font> covering our <font color="blue">cerebral oximeter</font> devices, the <font color="blue">sensors used with</font>     these devices, or a similar invention, we may have to <font color="blue">participate</font> in an     <font color="blue">adversarial proceeding known as</font> an <font color="blue">interference</font>, which is declared by the     <font color="blue">US Patent and Trademark Office</font> to determine priority of invention in the     United  States</td>
    </tr>
    <tr>
      <td>It  is  possible  that  we may be <font color="blue">unsuccessful</font> in the     <font color="blue">interference</font>, resulting in a loss of some or all of our US patent claims</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also face</font> similar <font color="blue"><font color="blue">proceedings</font> outside</font> the <font color="blue">United States</font>, including     <font color="blue">oppositions</font>, to determine priority of invention or <font color="blue">patentability</font></td>
    </tr>
    <tr>
      <td>Even if we     are successful in these <font color="blue">proceedings</font>, we may incur substantial costs, and the     time  and attention of our <font color="blue">management</font> and <font color="blue">scientific personnel will</font> be     diverted in pursuit of these <font color="blue">proceedings</font></td>
    </tr>
    <tr>
      <td>Moreover, the laws of some foreign     <font color="blue">jurisdictions</font> may not protect <font color="blue"><font color="blue">intellectual property</font> rights</font> to the same     extent  as  in  the <font color="blue">United States</font>, and many companies have <font color="blue">encountered</font>     <font color="blue">significant</font> <font color="blue"><font color="blue">difficult</font>ies</font> in protecting and defending <font color="blue">such rights</font> in foreign     <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>If  we encounter such <font color="blue"><font color="blue">difficult</font>ies</font> or we are otherwise     precluded from <font color="blue"><font color="blue">effective</font>ly</font> protecting our <font color="blue"><font color="blue">intellectual property</font> rights</font> in     foreign <font color="blue">jurisdictions</font>, we may incur substantial costs and our business     <font color="blue">prospects could</font> be <font color="blue">substantially</font> harmed</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on trade secret</font> and <font color="blue">copyright protection</font> to protect our     interests in <font color="blue">proprietary</font> information and know-how, and for processes for     which  patents are undesirable to obtain or are <font color="blue">difficult</font> to obtain or     enforce</td>
    </tr>
    <tr>
      <td>We may not be able to protect our <font color="blue">trade secrets</font> or <font color="blue">copyrights</font>     <font color="blue">adequately</font></td>
    </tr>
    <tr>
      <td>For example, none of our <font color="blue">copyrights</font> have <font color="blue">been registered with</font>     the US Copyright Office, <font color="blue">which limits</font> our ability to sue for and collect     <font color="blue">damages from <font color="blue">third party</font> infringers</font></td>
    </tr>
    <tr>
      <td>In addition, we rely on non-<font color="blue">disclosure</font>     and confidentiality <font color="blue"><font color="blue">agreement</font>s</font> with employees, consultants and other parties     to protect, in part, <font color="blue">trade secrets</font> and other <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> may</font> be breached, and we may not have <font color="blue">adequate remedies</font> for any     breach</td>
    </tr>
    <tr>
      <td>Moreover, others may in<font color="blue">dependent</font>ly develop equivalent <font color="blue">proprietary</font>     information,  and <font color="blue">third parties may otherwise gain access</font> to our trade     secrets and <font color="blue">proprietary</font> knowledge</td>
    </tr>
    <tr>
      <td>Any <font color="blue">disclosure</font> of <font color="blue">confidential data into</font>     the <font color="blue">public domain</font> or to <font color="blue">third parties could allow</font> our <font color="blue">competitors</font> to learn     our <font color="blue">trade secrets</font> and use the information in <font color="blue">competition</font> <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>If we are found to infringe or are alleged to infringe any <font color="blue">third party</font>     <font color="blue"><font color="blue">intellectual property</font> rights</font>, then our business may be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>There are numerous US and foreign <font color="blue">issued patents</font> and pending     patent <font color="blue"><font color="blue">application</font>s</font> owned <font color="blue">by third parties</font> with patent claims in the field     of tissue or organic matter oximetry, including <font color="blue">cerebral oximetry</font> and areas     that are the focus of our product <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>We are aware of     patents owned <font color="blue">by third parties</font>, to which we do not have licenses, that     relate to, among other things, <font color="blue">optical spectroscopy</font> and the <font color="blue">interaction</font> of     <font color="blue">light with tissue</font> and <font color="blue">optical spectroscopy</font> in the area of <font color="blue">brain metabolism</font></td>
    </tr>
    <tr>
      <td>For example, possible <font color="blue">competitors</font> own patents that are directed to the     non-invasive determination of <font color="blue">blood oxygen saturation levels with</font> a near     infra-red spectrophotometric sensor and to an apparatus for <font color="blue">measuring oxygen</font>     saturation in blood using two <font color="blue">different</font> wavelengths of light</td>
    </tr>
    <tr>
      <td>There may be     other patents in addition to those of which we are aware that relate to     aspects of our <font color="blue">technology</font> and that <font color="blue">may materially</font> and <font color="blue">adversely</font> affect our     business</td>
    </tr>
    <tr>
      <td>Moreover, because patent <font color="blue"><font color="blue">application</font>s</font> can take many years to     issue, there may be currently pending <font color="blue"><font color="blue">application</font>s</font>, unknown to us, which may     later result in <font color="blue">issued patents</font> that pose a material risk to us</td>
    </tr>
    <tr>
      <td>We may pose a threat to companies who own or <font color="blue">control patents</font>     relating  to  <font color="blue">cerebral oximetry</font> systems or their <font color="blue">components</font>, or to the     <font color="blue">manufacture</font> and use of <font color="blue">such systems</font>, and one or more <font color="blue">third parties may file</font>     a lawsuit asserting a <font color="blue">patent <font color="blue">infringement</font></font> claim against the <font color="blue">manufacture</font>, use     or sale of the <font color="blue">INVOS System </font><font color="blue">based on</font> one or more of these patents</td>
    </tr>
    <tr>
      <td>We are     not aware of any <font color="blue">infringement</font> of the claims of any <font color="blue">issued patents</font> by our     products, and no charge of <font color="blue">patent <font color="blue">infringement</font></font> has been asserted <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>However, potential <font color="blue">competitors</font> would have more                                         27       _________________________________________________________________    [57]Table of <font color="blue">Contents       </font>incentive to assert <font color="blue">infringement</font> claims or challenge our patents if a more     <font color="blue">significant</font> market for the <font color="blue">INVOS System </font>develops</td>
    </tr>
    <tr>
      <td>Whether the <font color="blue">manufacture</font>, sale or use of the INVOS System, or     whether  any products under <font color="blue">development</font> would, upon <font color="blue">commercialization</font>,     infringe any patent claim will not be known with <font color="blue">certainty</font> unless and until     a court <font color="blue">interprets</font> the patent claim in the context of <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>If an     <font color="blue">infringement</font> <font color="blue">allegation</font> is made <font color="blue">against us</font>, we may seek to invalidate the     asserted patent claim and/or to allege non-<font color="blue">infringement</font> of the asserted     patent claim</td>
    </tr>
    <tr>
      <td>In order for us to invalidate a US patent claim, we would     need to rebut the <font color="blue">presumption</font> of <font color="blue">validity afforded</font> to <font color="blue">issued patents</font> in the     <font color="blue">United States</font> with clear and <font color="blue">convincing evidence</font> of invalidity, which is a     <font color="blue">high burden</font> of proof</td>
    </tr>
    <tr>
      <td>The outcome of <font color="blue">infringement</font> <font color="blue">litigation</font> is subject to substantial     <font color="blue">uncertainties</font>, especially in medical device-related patent cases that may,     for example, turn on the <font color="blue">interpretation</font> of patent claim <font color="blue">language by</font> the     <font color="blue">court which may</font> not be to our advantage, and also the testimony of experts     as  to <font color="blue">technical facts upon which experts may reasonably</font> disagree</td>
    </tr>
    <tr>
      <td>Our     defense of an <font color="blue">infringement</font> <font color="blue">litigation</font> lawsuit could result in <font color="blue">significant</font>     expense</td>
    </tr>
    <tr>
      <td><font color="blue">Regardless  </font>of  the  outcome,  <font color="blue">infringement</font> <font color="blue">litigation</font> could     <font color="blue">significant</font>ly disrupt our marketing, <font color="blue">development</font> and <font color="blue">commercialization</font>     efforts, divert our <font color="blue">management</font>’s attention and quickly consume our financial     resources</td>
    </tr>
    <tr>
      <td>In the event that we are found to infringe any valid claim in a     patent held by a <font color="blue">third party</font>, we may, among other things, be required to:       •   pay damages, including up to <font color="blue">treble damages</font> and the other party’s     attorneys’ fees, which may be substantial;         •   cease the <font color="blue">development</font>, <font color="blue">manufacture</font>, importation, use and sale of     products that infringe the <font color="blue">patent rights</font> of others, including our INVOS     System, through a court-imposed sanction called an injunction;         •   expend <font color="blue">significant</font> resources to redesign our <font color="blue">technology</font> so that it     does  not  infringe  others’  patent  rights, or to develop or acquire     non-infringing <font color="blue">intellectual property</font>, which may not be possible;         •   discontinue <font color="blue">manufacturing</font> or other <font color="blue">processes incorporating infringing</font>     <font color="blue">technology</font>; and/or         •   obtain licenses to the infringed <font color="blue">intellectual property</font>, which may not     be available to us on acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>Any <font color="blue">development</font> or <font color="blue">acquisition</font> of non-infringing products or     <font color="blue">technology</font> or <font color="blue">licenses could</font> require the <font color="blue">expenditure</font> of substantial time and     other resources and could have a material adverse effect on our business and     financial results</td>
    </tr>
    <tr>
      <td>If we are required to, but cannot, obtain a license to     valid <font color="blue">patent rights</font> held by a <font color="blue">third party</font>, we <font color="blue">would likely</font> be <font color="blue">prevented from</font>     <font color="blue">commercializing</font> the <font color="blue">relevant product</font>, or from further <font color="blue">manufacture</font>, sale or     use  of the <font color="blue">relevant product</font></td>
    </tr>
    <tr>
      <td>If we need to <font color="blue">redesign products</font> to avoid     third-party patents, we may suffer <font color="blue">significant</font> <font color="blue">regulatory</font> delays associated     with conducting <font color="blue">additional</font> studies or submitting technical, <font color="blue">manufacturing</font> or     other information related to the <font color="blue">redesigned product</font> and, ultimately, in     obtaining approval</td>
    </tr>
    <tr>
      <td>While  our  products  are  in  <font color="blue">clinical trials</font>, and prior to     <font color="blue">commercialization</font>, we believe our <font color="blue">activities</font> in the <font color="blue">United States</font> related to     the submission of data to the FDA fall within the scope of the <font color="blue">exemptions</font>     that cover <font color="blue">activities</font> related to developing information for submission to     the FDA and fall under general <font color="blue">investigational</font> use or similar laws in other     countries</td>
    </tr>
    <tr>
      <td>However, the US <font color="blue">exemptions</font> would not cover the <font color="blue">manufacturing</font>,     sale or use of <font color="blue">products which</font> are no longer in <font color="blue">clinical trials</font>, or other     <font color="blue">activities</font> in the <font color="blue">United States</font> that support overseas <font color="blue">clinical trials</font> if     those <font color="blue">activities</font> are not <font color="blue">also reasonably</font> related to developing information     for submission to the FDA In any event, the fact that no <font color="blue">third party</font> has     asserted a <font color="blue">patent <font color="blue">infringement</font></font> claim <font color="blue">against us</font> to date should not be taken     as an <font color="blue">indication</font>, or a level of comfort, that a <font color="blue">patent <font color="blue">infringement</font></font> claim     will not be asserted <font color="blue">against us</font> prior to or upon <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Some of our <font color="blue"><font color="blue">agreement</font>s</font>, including our <font color="blue">distribution</font> and sales     <font color="blue">representative</font> <font color="blue"><font color="blue">agreement</font>s</font> require us to indemnify the other party in certain     <font color="blue">circumstances</font> where our products have <font color="blue">been found</font> to infringe a patent or     other <font color="blue">proprietary</font> rights of others</td>
    </tr>
    <tr>
      <td>An <font color="blue">indemnification</font> claim <font color="blue">against us</font> may     require us to pay substantial sums to the <font color="blue">indemnified party</font>, including its     attorneys’ fees</td>
    </tr>
    <tr>
      <td>28       _________________________________________________________________    [58]Table of <font color="blue">Contents       </font>Our <font color="blue">success depends on</font> our ability to attract and retain <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>Our  future  performance  depends in <font color="blue">significant</font> part on the     <font color="blue">continued service</font> of our senior <font color="blue">management</font>, including Bruce J Barrett, our     President and Chief Executive Officer, and various scientific, technical and     <font color="blue">manufacturing</font> personnel</td>
    </tr>
    <tr>
      <td>Our loss of any of these <font color="blue">key personnel</font> could have     an adverse effect on us</td>
    </tr>
    <tr>
      <td>We do not maintain key-man life insurance on any of     our <font color="blue">key personnel</font>, and our <font color="blue">employment <font color="blue">agreement</font> with</font> Mr</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">competition</font> for <font color="blue">qualified employees</font> is     intense, and if we are unable to attract, retain and motivate <font color="blue">additional</font>,     highly-skilled employees required for the expansion of our <font color="blue">operations</font>, our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font> could be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be able to retain our existing     personnel or attract <font color="blue">additional</font>, qualified persons when required and on     acceptable terms</td>
    </tr>
    <tr>
      <td>Any  <font color="blue">acquisition</font>s that we make <font color="blue">could disrupt</font> our business and harm our     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>From time to time, we evaluate potential strategic <font color="blue">acquisition</font>s of     complementary businesses, products or <font color="blue">technologies</font>, as well as consider     <font color="blue">joint ventures</font> and other <font color="blue">collaborative</font> projects</td>
    </tr>
    <tr>
      <td>We may not be able to     identify  appropriate <font color="blue">acquisition</font> candidates or <font color="blue">strategic partners</font>, or     successfully negotiate, finance or integrate any businesses, products or     <font color="blue">technologies</font> that we acquire</td>
    </tr>
    <tr>
      <td>We do not have any experience with acquiring     companies or products, other than the <font color="blue"><font color="blue">CorRestore </font>System</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">acquisition</font> we     <font color="blue">pursue could diminish</font> our <font color="blue">cash otherwise available</font> to us for other uses or     be dilutive to our <font color="blue">shareholders</font>, and could divert <font color="blue">management</font>’s time and     <font color="blue">resources from</font> our core <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have had limited success in marketing the <font color="blue"><font color="blue">CorRestore </font>System</font>, <font color="blue">which could</font>     result in claims <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Since we acquired rights in the <font color="blue"><font color="blue">CorRestore </font>System</font> in 2000, we have     had limited success in marketing the system</td>
    </tr>
    <tr>
      <td><font color="blue">The <font color="blue">CorRestore </font></font><font color="blue">system competes</font>     <font color="blue">against existing patches also used</font> for <font color="blue">cardiac reconstruction</font> and repair     that are <font color="blue">significant</font>ly less expensive and <font color="blue">at least one study indicates</font> are     <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>We  also  compete  <font color="blue">against alternative methods</font> of treating     <font color="blue">congestive heart failure</font></td>
    </tr>
    <tr>
      <td>Surgical Ventricular Restoration, or SVR, is in     the <font color="blue">early stages</font> of its <font color="blue">development</font> and <font color="blue">will likely</font> require <font color="blue">significant</font>     clinical  studies  before it is <font color="blue">widely accepted</font></td>
    </tr>
    <tr>
      <td>There are many larger     companies in this industry that have <font color="blue">significant</font>ly larger research and     <font color="blue">development</font> budgets than ours</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may be able to develop <font color="blue">additional</font>     or <font color="blue">better treatments</font> for <font color="blue">congestive heart failure</font> and may be able to take     advantage  of the <font color="blue">significant</font> time and effort we have invested to gain     medical <font color="blue">acceptance</font> of SVR surgeries</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent</font> on a <font color="blue">third party</font> to <font color="blue">manufacture</font> the <font color="blue">CorRestore </font>    System</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">license <font color="blue">agreement</font></font> limits</font> the parties that we may engage</td>
    </tr>
    <tr>
      <td>The     <font color="blue">ultimate success</font> of our <font color="blue">CorRestore </font>business is <font color="blue">dependent</font> on our ability to     manage the <font color="blue">manufacture</font>r of the <font color="blue"><font color="blue">CorRestore </font>System</font></td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in     managing the <font color="blue">manufacture</font>r of the <font color="blue"><font color="blue">CorRestore </font>System</font>, our business could be     <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">entered into</font> a <font color="blue"><font color="blue">license <font color="blue">agreement</font></font> with respect</font> to the <font color="blue">CorRestore </font>    System in 2002</td>
    </tr>
    <tr>
      <td>Although we believe we have <font color="blue">complied with</font> our <font color="blue">obligations</font>     under the <font color="blue">license <font color="blue">agreement</font></font>, our limited success in marketing the <font color="blue">CorRestore </font>    System could result in claims <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>As part of the <font color="blue">compensation</font> for     the <font color="blue">acquisition</font> of our <font color="blue">CorRestore </font>licenses, we issued five-year warrants to     purchase  an  aggregate of 2cmam100cmam000 <font color="blue">common shares</font> at dlra3dtta00 per share,     exercisable <font color="blue">based on</font> our <font color="blue">cumulative net sales</font> of the <font color="blue"><font color="blue">CorRestore </font>System</font>     products</td>
    </tr>
    <tr>
      <td>We do not expect the sales <font color="blue">requirements</font> for exercise of these     warrants  to  be met before the November 2006 expiration date of these     warrants</td>
    </tr>
    <tr>
      <td><font color="blue">Expiration </font>of these warrants before they become exercisable could     cause the holders of these warrants to make claims <font color="blue">against us</font> under the     <font color="blue">license <font color="blue">agreement</font></font></td>
    </tr>
    <tr>
      <td>If we are required to pay any <font color="blue"><font color="blue">significant</font> amounts</font> to     defend or as a result of any such claims, our results of <font color="blue">operations</font> would be     <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Risks Relating to Our Common Shares     If we were to complete a <font color="blue">public offering</font>, we would have <font color="blue">broad discretion</font> to     determine how to allocate the net proceeds of that offering and may not use     them <font color="blue"><font color="blue">effective</font>ly</font></td>
    </tr>
    <tr>
      <td>If we were to complete a <font color="blue">public offering</font> of <font color="blue">common shares</font>, we     <font color="blue">would intend</font> to use the net proceeds of that <font color="blue">offering primarily</font> to expand     our <font color="blue">direct sales team</font> and other sales and marketing <font color="blue">activities</font>, sponsor     <font color="blue">additional</font> <font color="blue">clinical trials</font> and expand our                                         29       _________________________________________________________________    [59]Table of <font color="blue">Contents       </font>research  and  <font color="blue">development</font> efforts and for working capital and general     <font color="blue">corporate purposes</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of the net proceeds of any such     offering  would  be allocated to working capital and <font color="blue">general corporate</font>     purposes</td>
    </tr>
    <tr>
      <td>We would be <font color="blue">raising money</font> for these purposes to strengthen our     <font color="blue">balance sheet</font> and <font color="blue">provide us with greater flexibility</font> in <font color="blue">implementing</font> our     business  plans  and  responding  to  future  business  <font color="blue">conditions</font> and     <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>We would retain <font color="blue">broad discretion</font> to determine how to allocate     the net proceeds of our proposed <font color="blue">public offering</font> of <font color="blue">common shares</font> and the     timing of the payments</td>
    </tr>
    <tr>
      <td>If we fail to apply these funds <font color="blue"><font color="blue">effective</font>ly</font>, the     <font color="blue">failure could</font> result in <font color="blue">financial losses</font> that could have a material adverse     effect on our business and cause the price of our <font color="blue">common shares</font> to decline</td>
    </tr>
    <tr>
      <td><font color="blue">Pending  </font>the <font color="blue">application</font> of such potential proceeds, we intend to keep     sufficient net proceeds of sales of <font color="blue">common shares</font> in cash and bank <font color="blue">accounts</font>     to avoid becoming an <font color="blue">inadvertent</font> <font color="blue">investment</font> company subject to regulation     under <font color="blue">the Investment Company Act </font>of 1940</td>
    </tr>
    <tr>
      <td>The <font color="blue">remaining proceeds would</font> be     expected to be invested in short-term, US <font color="blue">government</font> or other <font color="blue">investment</font>     grade, interest-bearing <font color="blue">investment</font>s</td>
    </tr>
    <tr>
      <td>These <font color="blue">restrictions</font> on our <font color="blue">investment</font>s     <font color="blue">might limit</font> the income otherwise available from investing these funds,     lowering our income and <font color="blue">potentially</font> decreasing our earnings and the price of     our <font color="blue">common shares</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our corporate charter <font color="blue">documents</font> and Michigan <font color="blue">law may delay</font> or     <font color="blue">prevent attempts by</font> our <font color="blue">shareholders</font> to change our <font color="blue">management</font> and hinder     efforts to acquire a <font color="blue">controlling interest</font> in us</td>
    </tr>
    <tr>
      <td>Our board of <font color="blue">directors</font> has the authority, without further approval     of  our  <font color="blue">shareholders</font>,  to  <font color="blue">issue <font color="blue">preferred shares</font></font> having <font color="blue">such rights</font>,     <font color="blue">preferences</font> and <font color="blue">privileges as</font> the <font color="blue">board may</font> determine</td>
    </tr>
    <tr>
      <td>Any <font color="blue">such issuance</font> of     preferred  shares  could, under some <font color="blue">circumstances</font>, have the effect of     delaying or preventing a change in control of us and might <font color="blue">adversely</font> affect     the rights of holders of <font color="blue">common shares</font></td>
    </tr>
    <tr>
      <td>In addition, we are subject to     Michigan <font color="blue">statutes regulating</font> business combinations, takeovers and control     share <font color="blue">acquisition</font>s, which <font color="blue">might also</font> hinder or delay a change in control of     our  company</td>
    </tr>
    <tr>
      <td>Anti-takeover  provisions that could be included in the     <font color="blue">preferred shares</font> when issued and the Michigan <font color="blue">statutes regulating</font> business     combinations, takeovers and control share <font color="blue">acquisition</font>s can depress the     <font color="blue">market price</font> of our securities and can limit the <font color="blue">shareholders</font>’ ability to     receive a <font color="blue">premium on</font> their <font color="blue">shares by discouraging takeover</font> and <font color="blue">tender offer</font>     bids, even if <font color="blue">such events could</font> be viewed <font color="blue">as beneficial by</font> our <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">directors</font> serve staggered three-year terms, and <font color="blue">directors</font> may     be <font color="blue">removed only</font> for cause by a vote of the holders of a majority of the     <font color="blue">shares entitled</font> to vote at an election of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Our Restated Articles     of Incorporation also set the minimum number of <font color="blue">directors</font> constituting the     <font color="blue">entire board at three</font> and the <font color="blue">maximum at fifteen</font>, and they require approval     of holders of 90 percent of our <font color="blue">voting shares</font> to amend these provisions</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">bylaws contain procedures</font>, including notice <font color="blue">requirements</font>, for nominating     persons for election to our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions could</font> have     an anti-takeover effect by making it more <font color="blue">difficult</font> to acquire our company     by means of a <font color="blue">tender offer</font>, a <font color="blue">proxy contest</font> or otherwise or by removing     <font color="blue">incumbent officers</font> and <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>These provisions <font color="blue">could delay</font>, deter or     prevent a <font color="blue">tender offer</font> or <font color="blue">takeover attempt</font> that a <font color="blue">shareholder might</font> consider     in his or her <font color="blue">best interests</font>, including those attempts that might result in     a  premium  over  the  market  price for the <font color="blue">common shares</font> held by our     <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common shares</font> has <font color="blue">been volatile</font> and <font color="blue">may continue</font> to     remain so</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common shares</font> has <font color="blue">been highly volatile</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">following could</font> cause the <font color="blue">market price</font> of the <font color="blue">common shares</font> to continue     to fluctuate <font color="blue">substantially</font>:       •   changes in our quarterly <font color="blue">financial condition</font> or operating results;         •   changes in general <font color="blue">conditions</font> in the economy;         •   changes in the <font color="blue">financial markets</font>;         •   changes in the <font color="blue">medical equipment industry</font>;         •   changes in financial estimates by securities analysts or <font color="blue">differences</font>     between those estimates and our actual results;         •   the liquidity of the market for the <font color="blue">common shares</font>;         •   <font color="blue">development</font>s with respect to patents and <font color="blue">proprietary</font> rights;         •   <font color="blue">publication</font> of <font color="blue">clinical research</font> results regarding our products;                                         30       _________________________________________________________________    [60]Table of <font color="blue">Contents       </font>  •   changes in <font color="blue">health care policies</font> in the <font color="blue">United States</font> or foreign     countries;         •   grants or exercises of <font color="blue">stock options</font> or warrants;         •   news <font color="blue">announcements</font>;         •   <font color="blue">litigation</font> involving us;         •   actions by <font color="blue">government</font>al agencies, including the FDA, or changes in     <font color="blue">regulations</font>; and         •   other <font color="blue">development</font>s <font color="blue">affecting</font> us or our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>In particular, the <font color="blue">stock market might</font> experience <font color="blue">significant</font> price and     volume <font color="blue">fluctuations</font> that <font color="blue">might affect</font> the <font color="blue">market price</font> of the <font color="blue">common shares</font>     for reasons that are unrelated to our operating performance and that are     beyond our control</td>
    </tr>
    <tr>
      <td>We  have <font color="blue">never paid <font color="blue">cash dividends</font> on</font> our <font color="blue">capital stock</font>, and we do not     anticipate paying any <font color="blue">cash dividends</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">never paid <font color="blue">cash dividends</font> on</font> our <font color="blue">common shares</font> and do not     expect to <font color="blue">pay dividends</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">currently intend</font> to     retain any <font color="blue">future earnings</font> for use in our business</td>
    </tr>
    <tr>
      <td>The payment of any     <font color="blue">future dividends will</font> be determined by the board in light of the <font color="blue">conditions</font>     <font color="blue">then existing</font>, including our <font color="blue">financial condition</font> and <font color="blue">requirements</font>, future     prospects, <font color="blue">restrictions</font> in financing <font color="blue"><font color="blue">agreement</font>s</font>, business <font color="blue">conditions</font> and     other  factors  deemed  relevant  by  the  board</td>
    </tr>
    <tr>
      <td>As a result, capital     <font color="blue">appreciation</font>, if any, of our <font color="blue">common shares</font> will be your sole source of gain     for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of the <font color="blue">common shares</font> might be lower because of shares     eligible for future sale and <font color="blue">shares reserved</font> for <font color="blue">future <font color="blue">issuance upon</font></font> the     exercise of options and warrants we have granted</td>
    </tr>
    <tr>
      <td>Future sales of substantial amounts of <font color="blue">common shares</font> in the public     market or the <font color="blue">perception</font> that <font color="blue">such sales could</font> occur <font color="blue">could <font color="blue">adversely</font></font> affect     the <font color="blue">market price</font> of the <font color="blue">common shares</font></td>
    </tr>
    <tr>
      <td>Any substantial sale of <font color="blue">common shares</font>     or even the <font color="blue">possibility</font> of such sales occurring may have an adverse effect     on the <font color="blue">market price</font> of the <font color="blue">common shares</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">outstanding options</font> and     warrants to purchase an aggregate of 4cmam014cmam232 <font color="blue">common shares</font></td>
    </tr>
    <tr>
      <td>We have also     reserved  up  to an <font color="blue">additional</font> 505cmam785 <font color="blue">common shares</font> for <font color="blue">issuance upon</font>     exercises of options or awards of <font color="blue">restricted stock</font> or <font color="blue">restricted stock</font> units     which have not yet <font color="blue">been granted</font> or <font color="blue">awarded under</font> our <font color="blue">stock incentive</font> plans</td>
    </tr>
    <tr>
      <td>We have <font color="blue">effective</font> registration statements for the <font color="blue">shares underlying</font> these     options and <font color="blue">stock awards</font></td>
    </tr>
    <tr>
      <td>Therefore, except for <font color="blue">volume limitations imposed</font>     by <font color="blue">Securities and Exchange Commission Rule </font>144, these shares are freely     tradeable</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common shares</font> could fall if the holders     of these <font color="blue">shares sell them</font> or are perceived by the <font color="blue">market as intending</font> to     sell them</td>
    </tr>
    <tr>
      <td>Forward-Looking Statements               Some  of  the  statements in this report are forward-looking     statements</td>
    </tr>
    <tr>
      <td>These forward-looking statements include statements relating to     our performance in the <font color="blue">sections entitled</font> “<font color="blue">Risk Factors</font>,” “Management’s     Discussion and Analysis of Financial Condition and Results of Operations”     and “Business” and elsewhere in this report</td>
    </tr>
    <tr>
      <td>Forward-looking statements     include statements regarding the intent, belief or <font color="blue">current expectations</font> of     us or our <font color="blue">management</font>, including statements preceded by, followed by or     including forward-looking terminology such as “may,” “will,” “should,”     “believe,”   “expect,”   “anticipate,”  “plan,”  “intend,”  “propose,”     “estimate,” “continue,” “predict” or similar expressions, with respect to     <font color="blue">various matters</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">statements involve known</font> and unknown risks, <font color="blue">uncertainties</font>     and other <font color="blue">factors which may</font> cause our actual results, performance time     frames or <font color="blue">achievements</font> to be materially <font color="blue">different</font> from any future results,     performance,  time  frames or <font color="blue">achievements</font> expressed or implied by the     forward-looking statements</td>
    </tr>
    <tr>
      <td>We discuss                                         31       _________________________________________________________________    [61]Table of <font color="blue">Contents       </font>many of these risks, <font color="blue">uncertainties</font> and other factors in this report in     greater  detail  under  the heading “<font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>” Given these risks,     <font color="blue">uncertainties</font> and other factors, you should not place <font color="blue">undue reliance on</font>     these forward-looking statements</td>
    </tr>
    <tr>
      <td>Also, these forward-looking statements     represent our estimates and <font color="blue">assumptions</font> only as of the date of this report</td>
    </tr>
    <tr>
      <td>You should read this report and the <font color="blue">documents</font> that we have <font color="blue">filed as exhibits</font>     and  <font color="blue">incorporated</font>  by reference to this report <font color="blue">completely</font> and with the     understanding that our <font color="blue">actual future</font> results may be materially <font color="blue">different</font>     from what we expect</td>
    </tr>
    <tr>
      <td>We <font color="blue">hereby qualify</font> all of our forward-looking statements     by these <font color="blue">cautionary</font> statements</td>
    </tr>
    <tr>
      <td>All  forward-looking  statements in this report are <font color="blue">based on</font>     information available to us on the date of this report</td>
    </tr>
  </tbody>
</table>